Alcon Beheer

Beheer criteriumcontroles 3/4

De CEO Alcon is David Endicott, benoemd in Jul2018, heeft een ambtstermijn van 6.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.33M, bestaande uit 10.7% salaris en 89.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.047% van de aandelen van het bedrijf, ter waarde CHF 18.26M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 5.8 jaar.

Belangrijke informatie

David Endicott

Algemeen directeur

US$12.3m

Totale compensatie

Percentage CEO-salaris	10.7%
Dienstverband CEO	6.3yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is David Endicott's beloning veranderd ten opzichte van Alcon's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$1b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$12m	US$1m	US$974m
Sep 30 2023	n/a	n/a	US$450m
Jun 30 2023	n/a	n/a	US$362m
Mar 31 2023	n/a	n/a	US$341m
Dec 31 2022	US$10m	US$1m	US$335m
Sep 30 2022	n/a	n/a	US$571m
Jun 30 2022	n/a	n/a	US$457m
Mar 31 2022	n/a	n/a	US$460m
Dec 31 2021	US$11m	US$1m	US$376m
Sep 30 2021	n/a	n/a	US$332m
Jun 30 2021	n/a	n/a	US$183m
Mar 31 2021	n/a	n/a	-US$390m
Dec 31 2020	US$8m	US$1m	-US$531m
Sep 30 2020	n/a	n/a	-US$717m
Jun 30 2020	n/a	n/a	-US$636m
Mar 31 2020	n/a	n/a	-US$604m
Dec 31 2019	US$7m	US$1m	-US$656m

Compensatie versus markt: De totale vergoeding ($USD 12.33M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 5.78M ).

Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

David Endicott (59 yo)

6.3yrs

Tenure

US$12,325,391

Compensatie

Mr. David J. Endicott is President and Chief Executive Officer at Aerie Pharmaceuticals, Inc. since November 21, 2022. He had been the Chief Executive Officer of Alcon, Inc. since July 1, 2018. He is the C...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
F. Ball	Executive Chairman	5.8yrs	US$1.17m	0.011% CHF 4.4m
David Endicott	CEO & Director	6.3yrs	US$12.33m	0.047% CHF 18.3m
Arthur Cummings	Executive Director	no data	US$284.68k	0.0012% CHF 453.6k
Timothy Stonesifer	Senior VP & CFO	5.6yrs	geen gegevens	0.020% CHF 7.6m
Ian Bell	Senior VP & COO	less than a year	geen gegevens	0.0081% CHF 3.2m
Margaret Buckley	Chief Accounting Officer	no data	geen gegevens	geen gegevens
Franck Leveiller	SVP of Global Research & Development and Chief Scientific Officer	2.4yrs	geen gegevens	geen gegevens
Muru Murugappan	Senior VP and Chief Information & Transformation Officer	no data	geen gegevens	geen gegevens
Royce Bedward	Senior VP	no data	geen gegevens	geen gegevens
Kimberly Martin	Senior VP	4.3yrs	geen gegevens	geen gegevens
Laurent Attias	SVP of Corporate Strategy	no data	geen gegevens	0.0040% CHF 1.5m
Leon Sergio Fraustro	Senior VP & President of Americas	9.3yrs	geen gegevens	0.0043% CHF 1.7m

5.0yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0A0D wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
F. Ball	Executive Chairman	5.8yrs	US$1.17m	0.011% CHF 4.4m
David Endicott	CEO & Director	5.8yrs	US$12.33m	0.047% CHF 18.3m
Arthur Cummings	Executive Director	5.8yrs	US$284.68k	0.0012% CHF 453.6k
Karen May	Independent Director	5.8yrs	US$325.52k	0.0052% CHF 2.0m
D. Grossman	Independent Vice Chair	5.8yrs	US$361.69k	0.0031% CHF 1.2m
Thomas Glanzmann	Independent Director	5.8yrs	US$352.98k	0.0041% CHF 1.6m
Dieter Spälti	Independent Director	5.8yrs	US$236.83k	0.0049% CHF 1.9m
Scott Maw	Independent Director	5.8yrs	US$333.87k	0.0031% CHF 1.2m
Lynn Bleil	Independent Director	5.8yrs	US$296.31k	0.0019% CHF 756.0k
Ines Pöschel	Independent Director	5.8yrs	US$293.86k	0.0021% CHF 821.9k
RaQuel Bono	Independent Director	2.6yrs	US$256.66k	0.00056% CHF 217.1k

5.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0A0D wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Alcon Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Alcon Announces Management Changes

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc., Annual General Meeting, May 05, 2023

Insufficient new directors

Insufficient new directors

Alcon Inc., Annual General Meeting, Apr 28, 2021

Recent updates

Third quarter 2024 earnings released: EPS: US$0.53 (vs US$0.41 in 3Q 2023)

Alcon Inc. Revises Earnings Guidance for the Year 2024

Alcon Announces the U.S. Launch of PRECISION®, the Only One-Week Replacement Contact Lens

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: US$0.45 (vs US$0.34 in 2Q 2023)

Alcon Inc. Maintains Earnings Guidance for the Year 2024

Now 22% undervalued

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

First quarter 2024 earnings released: EPS: US$0.50 (vs US$0.35 in 1Q 2023)

Upcoming dividend of CHF0.24 per share

Alcon Inc. Approves Gross Dividend

Now 20% undervalued

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Dividend of CHF0.24 announced

Alcon Announces Management Changes

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings released: EPS: US$1.98 (vs US$0.68 in FY 2022)

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.41 (vs US$0.24 in 3Q 2022)

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

First quarter 2023 earnings released: EPS: US$0.35 (vs US$0.34 in 1Q 2022)

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.21 per share at 0.3% yield

Full year 2022 earnings released: EPS: US$0.68 (vs US$0.77 in FY 2021)

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Now 20% undervalued after recent price drop

Alcon Inc. Updates Earnings Guidance for the Year 2022

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Second quarter 2022 earnings released: EPS: US$0.30 (vs US$0.31 in 2Q 2021)

Alcon Inc. Revises Revenue Guidance for 2022

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.17 in 1Q 2021)

Alcon Inc. Declares Dividend for 2021

Insufficient new directors

Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery

Alcon Inc. Announces Launch of Clareon Portfolio in the U.S

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Alcon Inc. Proposes Dividend

Alcon Inc. Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe

Alcon Continues Its Successful Rollout of Precision1 Daily Disposable Contact Lenses, Now Available in Key Markets Throughout Latin America, Asia & Europe

Third quarter 2021 earnings released: EPS US$0.004 (vs US$0.30 loss in 3Q 2020)

President of Global Business & Innovation Michael Onuscheck has left the company

Second quarter 2021 earnings released: EPS US$0.31 (vs US$0.86 loss in 2Q 2020)

Alcon to Launch TOTAL30 as the First-and-Only Monthly Replacement, Water Gradient Contact Lens

First quarter 2021 earnings released: EPS US$0.17 (vs US$0.12 loss in 1Q 2020)

Alcon Inc. Provides Earnings Guidance for the Full Year 2021

Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S

Full year 2020 earnings released: US$1.09 loss per share (vs US$1.34 loss in FY 2019)

Revenue beats expectations

Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S

Alcon Launches PRECISION1 for Astigmatism Contact Lenses in the U.S

Alcon Inc. Announces Launch of AcrySof IQ Vivity, the First and Only Non-Diffractive Extended Depth of Focus Intraocular Lens in the U.S

Alcon Inc., Annual General Meeting, Apr 28, 2021

Alcon Canada Introduces AcrySof IQ Vivity, the Only Presbyopia-Correcting Intraocular Lens with X-WAVE Technology